Quality of life study for people with MGUS or smoldering myeloma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how patients feel day to day (quality of life) while they are monitored or treated for MGUS or smoldering multiple myeloma. It is designed for people who do NOT yet have “myeloma defining events” or amyloidosis, because the goal is to understand well-being in earlier disease stages.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re at least 18 years old.
- You have MGUS (monoclonal gammopathy of unknown significance) or smoldering multiple myeloma, as diagnosed by your tests.
- Your protein and bone marrow results must fit the study’s MGUS or smoldering myeloma ranges, and you must not have amyloidosis.
- Your situation must not show myeloma “defining events,” such as high calcium, major anemia, kidney problems, bone lesions, or certain concerning scan findings.
- You must be enrolled in an MD Anderson clinical trial for MGUS or smoldering myeloma (including specific listed studies or future ones at MD Anderson).
- You must speak English or Spanish.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational study that follows people with early blood findings that can be linked to multiple myeloma, to understand what happens over time. It does not test a new drug for most people; instead, it tracks health, lab results, and imaging to learn who may develop myeloma.
This study looks at two different “precursor” conditions that can happen before multiple myeloma: MGUS and smoldering myeloma (SMM). Researchers want to better tell which cases are more likely to progress, using blood/urine tests and sometimes bone marrow tissue.
This study tests non-chemotherapy supports meant to improve quality of life and immune health for people with multiple myeloma (or related conditions). Depending on the group, it may involve activities, nutrition, and/or a medication like a beta blocker.
This study is for people who are newly diagnosed with either a very early blood condition (MGUS or smoldering myeloma) or AL amyloidosis, and who have not yet had treatment. It aims to help doctors better diagnose and manage these conditions in Italy.
This trial tests whether a whole-food, plant-based eating pattern—plus supplements or placebo—can improve health outcomes in people with MGUS or smoldering multiple myeloma. You may be asked to follow specific recipes and stop certain supplements, so it helps to confirm you can stick with the plan.
This study tests whether a plant-based diet and certain supplements can help people with smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS). Participants will learn to cook plant-based recipes and track their meals using a phone app.
Hear when a new Monoclonal Gammopathy of Undetermined Significance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.